504 related articles for article (PubMed ID: 14960527)
1. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis.
Castéra L; Hézode C; Roudot-Thoraval F; Lonjon I; Zafrani ES; Pawlotsky JM; Dhumeaux D
Gut; 2004 Mar; 53(3):420-4. PubMed ID: 14960527
[TBL] [Abstract][Full Text] [Related]
2. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
3. Serum leptin and ghrelin in chronic hepatitis C patients with steatosis.
Pavlidis C; Panoutsopoulos GI; Tiniakos D; Koutsounas S; Vlachogiannakos J; Zouboulis-Vafiadis I
World J Gastroenterol; 2011 Dec; 17(46):5097-104. PubMed ID: 22171144
[TBL] [Abstract][Full Text] [Related]
4. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.
Petta S; Cammà C; Di Marco V; Cabibi D; Ciminnisi S; Caldarella R; Licata A; Massenti MF; Marchesini G; Craxì A
Antivir Ther; 2009; 14(5):631-9. PubMed ID: 19704165
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response.
Kumar D; Farrell GC; Fung C; George J
Hepatology; 2002 Nov; 36(5):1266-72. PubMed ID: 12395339
[TBL] [Abstract][Full Text] [Related]
6. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients.
Patton HM; Patel K; Behling C; Bylund D; Blatt LM; Vallée M; Heaton S; Conrad A; Pockros PJ; McHutchison JG
J Hepatol; 2004 Mar; 40(3):484-90. PubMed ID: 15123364
[TBL] [Abstract][Full Text] [Related]
7. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
Hung CH; Kuo FY; Wang JH; Lu SN; Hu TH; Chen CH; Lee CM; Eng HL
Antivir Ther; 2006; 11(4):483-9. PubMed ID: 16856622
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and impact of hepatic steatosis on the response to antiviral therapy in Saudi patients with genotypes 1 and 4 chronic hepatitis C.
AlQaraawi AM; Sanai FM; Al-Husseini H; Albenmousa A; AlSheikh A; Ahmed LR; Hersi A; Al-Otaibi MM; Syed M; Ali SM; Al-hamoudi W; Alswat KA; Abdo AA
Dig Dis Sci; 2011 Apr; 56(4):1222-8. PubMed ID: 20931285
[TBL] [Abstract][Full Text] [Related]
9. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
Cross TJ; Quaglia A; Nolan J; Hughes S; Harrison PM
J Med Virol; 2010 May; 82(6):958-64. PubMed ID: 20419809
[TBL] [Abstract][Full Text] [Related]
10. Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection.
Westin J; Lagging M; Dhillon AP; Norkrans G; Romero AI; Pawlotsky JM; Zeuzem S; Schalm SW; Verheij-Hart E; Negro F; Missale G; Neumann AU; Hellstrand K;
J Viral Hepat; 2007 Jan; 14(1):29-35. PubMed ID: 17212641
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.
Rubbia-Brandt L; Quadri R; Abid K; Giostra E; Malé PJ; Mentha G; Spahr L; Zarski JP; Borisch B; Hadengue A; Negro F
J Hepatol; 2000 Jul; 33(1):106-15. PubMed ID: 10905593
[TBL] [Abstract][Full Text] [Related]
12. Steatosis affects chronic hepatitis C progression in a genotype specific way.
Rubbia-Brandt L; Fabris P; Paganin S; Leandro G; Male PJ; Giostra E; Carlotto A; Bozzola L; Smedile A; Negro F
Gut; 2004 Mar; 53(3):406-12. PubMed ID: 14960525
[TBL] [Abstract][Full Text] [Related]
13. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.
Harrison SA; Brunt EM; Qazi RA; Oliver DA; Neuschwander-Tetri BA; Di Bisceglie AM; Bacon BR
Clin Gastroenterol Hepatol; 2005 Jun; 3(6):604-9. PubMed ID: 15952103
[TBL] [Abstract][Full Text] [Related]
14. Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
Reddy KR; Govindarajan S; Marcellin P; Bernstein D; Dienstag JL; Bodenheimer H; Rakela J; Messinger D; Schmidt G; Ackrill A; Hadziyannis SJ
J Viral Hepat; 2008 Feb; 15(2):129-36. PubMed ID: 18184196
[TBL] [Abstract][Full Text] [Related]
15. Steatosis as a predictive factor for treatment response in patients with chronic hepatitis C.
Antúnez I; Aponte N; Fernández-Carbia A; Rodríguez-Perez F; Toro DH
P R Health Sci J; 2004 Jun; 23(2 Suppl):57-60. PubMed ID: 16929588
[TBL] [Abstract][Full Text] [Related]
16. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.
Guedj H; Guedj J; Negro F; Lagging M; Westin J; Bochud PY; Bibert S; Neumann AU;
J Viral Hepat; 2012 Jul; 19(7):488-96. PubMed ID: 22676361
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
[TBL] [Abstract][Full Text] [Related]
18. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections.
Hézode C; Roudot-Thoraval F; Zafrani ES; Dhumeaux D; Pawlotsky JM
J Viral Hepat; 2004 Sep; 11(5):455-8. PubMed ID: 15357652
[TBL] [Abstract][Full Text] [Related]
19. Influence of steatosis on progression of fibrosis and virological response in chronic hepatitis C cases.
Rafi H; Kabbaj N; Salihoun M; Amrani L; Acharki M; Guedira M; Nya M; Amrani N
Arab J Gastroenterol; 2011 Sep; 12(3):136-8. PubMed ID: 22055591
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
